



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 13891

Title: Role of E3 ubiquitin ligases in Gastric Cancer.

Reviewer code: 02438007

Science editor: Ya-Juan Ma

Date sent for review: 2014-09-07 18:28

Date reviewed: 2014-09-18 15:53

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This manuscript makes an extensive review on E3 ubiquitin ligases function and its contribution to gastric cancer development. The role of E3 ubiquitin ligase inhibitors in the treatment of GC is also discussed. This review is useful and clearly.



ESPS PEER REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 13891

Title: Role of E3 ubiquitin ligases in Gastric Cancer.

Reviewer code: 00537853

Science editor: Ya-Juan Ma

Date sent for review: 2014-09-07 18:28

Date reviewed: 2014-09-23 21:20

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This review summarizes the role of E3 ubiquitin ligases in gastric cancer development, progression and prognosis. Furthermore, Authors aimed to discuss the preclinical and clinical studies of novel treatment strategies targeting aberrant E3 ubiquitin ligases in cancer patients. I believe that, to completely fit Authors' aim, the paragraph: "TARGETING E3 UBIQUITIN LIGASES FOR GASTRIC CANCER THERAPY" should be expanded. Several phrases should be also corrected: - Page 5: "MDM2 as a potential predictor for for benefit from adjuvant chemotherapy with fluorouracil-leucovorin-oxaliplatin (FLO) in resectable GC patients". - Page 10: "Some studies found that CHFR promoter methylation status may provide useful as a value predicting the malignant behaviors and molecular diagnostic marke for GC". - Page 12: "Despite further study is must which needs a better understanding of biological functions of many E3 ubiquitin ligases..".